Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

53.62 -2.16 (-3.87%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,119,715
Open 55.58
Bid (Size) 53.67 (500)
Ask (Size) 54.18 (700)
Prev. Close 55.78
Today's Range 53.59 - 56.12
52wk Range 26.76 - 59.30
Shares Outstanding 154,420,772
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth With a Tight Technical Breakout Setup ↗
Via Chartmill
News headline image
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share ↗
TG Therapeutics (NASDAQ:TGTX) Chairman, President and Chief Executive Officer Mike Weiss said the company’s multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous... 
Via MarketBeat

Performance

YTD
+83.1%
+83.1%
1 Month
-1.3%
-1.3%
3 Month
+0.2%
+0.2%
6 Month
+59.7%
+59.7%
1 Year
+48.4%
+48.4%

More News

Read More
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Via Investor Brand Network
TG Therapeutics (NASDAQ:TGTX): A Fitting Candidate for Affordable Growth ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth with a Breakout Setup ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Falls as Q2 Revenue Beats but EPS Misses, Guidance Raised Below Estimates ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Meets Minervini's Trend Template with Accelerating Growth ↗
Via Chartmill
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
News headline image
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
From BioMedWire
Via GlobeNewswire
TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength ↗
Via Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation ↗
Via Chartmill
News headline image
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection ↗
Via MarketBeat
News headline image
TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
TG Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Via The Motley Fool
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
TG Therapeutics Stock Surges After Drug Trial Update ↗
Via Benzinga
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
Via The Motley Fool
News headline image
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
TGTX Q1 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is TG Therapeutics, Inc. - Common Stock publicly traded?
Yes, TG Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does TG Therapeutics, Inc. - Common Stock trade on?
TG Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TG Therapeutics, Inc. - Common Stock?
The ticker symbol for TG Therapeutics, Inc. - Common Stock is TGTX on the Nasdaq Stock Market
What is the current price of TG Therapeutics, Inc. - Common Stock?
The current price of TG Therapeutics, Inc. - Common Stock is 53.62
When was TG Therapeutics, Inc. - Common Stock last traded?
The last trade of TG Therapeutics, Inc. - Common Stock was at 10/01/26 04:00 PM ET
What is the market capitalization of TG Therapeutics, Inc. - Common Stock?
The market capitalization of TG Therapeutics, Inc. - Common Stock is 8.28B
How many shares of TG Therapeutics, Inc. - Common Stock are outstanding?
TG Therapeutics, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.